PET Beyond FDG for Brain Tumors: SSTR, Amino Acid, and Emerging Tracers

Beyond FDG, somatostatin receptor PET (e.g., DOTATATE) offers high contrast for meningioma radiotherapy planning and patient selection for peptide receptor radionuclide therapy. Amino acid PET aids in distinguishing glioma progression from treatment-related change, improving res…

• SSTR PET (e.g., DOTATATE) is key for meningioma evaluation, aiding radiotherapy planning and peptide receptor radionuclide therapy selection.
• Amino acid PET improves differentiation of glioma recurrence from post-treatment changes.
• Emerging tracers targeting hormone receptors, hypoxia, and tumor neovasculature are expanding PET's biologic insights for brain tumors.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.